Clinical Trial News and Research

RSS

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return.

29 Mar 2015

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis has been accepted for review by the China Food and Drug Administration.

29 Mar 2015

Public volunteers to highlight their role in improving care for patients at Sheffield Consumers in Research event

RESEARCH-active members of the public are to showcase how their vital work helps shape clinical research projects and improves care for patients at a free drop-in event in Sheffield City Centre on Wednesday 22 April.

27 Mar 2015

Promising clinical trial results for ebola vaccines

Interim findings from a clinical trial (PREVAIL) in which two experimental Ebola vaccines were given to more than 600 people in Liberia indicate that the vaccines are safe for use in humans. Based on these positive results, the vaccines may continue into the next stage of clinical evaluation; a phase 3 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

27 Mar 2015

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus.

27 Mar 2015

Guinean Government initiates first efficacy trial of Ebola vaccine in Basse-Guinée

The Guinean Government with the World Health Organization initiated the very first efficacy trial of an Ebola vaccine this week in an affected community of the Basse-Guinée, one of the areas where most Ebola cases are found in the country.

27 Mar 2015

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth, a global leader in engineered cell therapies, today announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich.

27 Mar 2015

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.

26 Mar 2015

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A.

From Novo Nordisk 26 Mar 2015

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.

26 Mar 2015

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

AdverseEvents Inc., a leading healthcare informatics company, today launched RxCost, the first methodology to identify the total costs of adverse drug reactions (ADRs) associated with FDA-approved drugs.

26 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Marken secures Best Life Science Logistics Provider award

Marken announced today that they won the pharmaceutical clinical research industry award of Best Life Science Logistics Provider at the 5th Annual BioPharma Asia Industry Awards. The award was announced at a dinner and ceremony held in conjunction with the BioPharma Asia conference in Singapore, drawing an annual attendance of 1600.

25 Mar 2015

Only few studies demonstrate the effectiveness of marijuana

While many states have pushed for new laws to legalize the use of marijuana for medical reasons, there are few well-controlled studies that demonstrate its effectiveness.

25 Mar 2015

DNA samples collected from tampons may help detect endometrial cancer

Researchers at Mayo Clinic have shown that it is possible to detect endometrial cancer using tumor DNA picked up by ordinary tampons. The new approach specifically examines DNA samples from vaginal secretions for the presence of chemical "off" switches — known as methylation — that can disable genes that normally keep cancer in check.

25 Mar 2015

Norovirus vaccine may be available in the future

A multivalent candidate vaccine elicits broad antibody responses to a range of norovirus strains, including strains not included in the vaccine or previously encountered by participants, according to a new study published this week in PLOS Medicine.

25 Mar 2015

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

A Spanish study suggests that bosutinib can help improve or maintain response in patients with chronic myeloid leukaemia after treatment failure of three previous tyrosine kinase inhibitors.

24 Mar 2015

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

Confluence is a biopharmaceutical company focused on developing therapeutic treatments for Fragile X Syndrome and Autism Spectrum Disorders. AOP is an Austrian based company specializing in the development and marketing of medicines for rare and complex diseases.

24 Mar 2015

Clinical Trial News and Research

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

CFDA accepts WuXi MedImmune's novel anti-IL6 monoclonal antibody IND application for review

Public volunteers to highlight their role in improving care for patients at Sheffield Consumers in Research event

Promising clinical trial results for ebola vaccines

New Ebola vaccine shows promise in first phase 1 clinical trial

Guinean Government initiates first efficacy trial of Ebola vaccine in Basse-Guinée

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Brainstorm Cell Therapeutics provides business update, announces financial results for 2014

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Marken secures Best Life Science Logistics Provider award

Only few studies demonstrate the effectiveness of marijuana

DNA samples collected from tampons may help detect endometrial cancer

Norovirus vaccine may be available in the future

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Confluence pharmaceuticals signs co-development and marketing agreement with AOP orphan for fragile X syndrome drug

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery